» Articles » PMID: 33615140

Nanomedicine for COVID-19: the Role of Nanotechnology in the Treatment and Diagnosis of COVID-19

Overview
Journal Emergent Mater
Date 2021 Feb 22
PMID 33615140
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the recent outbreak of coronavirus 2019 (COVID-19). Although nearly two decades have passed since the emergence of pandemics such as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), no effective drug against the CoV family has yet been approved, so there is a need to find newer therapeutic targets. Currently, simultaneous research across the globe is being performed to discover efficient vaccines or drugs, including both conventional therapies used to treat previous similar diseases and emerging therapies like nanomedicine. Nanomedicine has already proven its value through its application drug delivery and nanosensors in other diseases. Nanomedicine and its components can play an important role in various stages of prevention, diagnosis, treatment, vaccination, and research related to COVID-19. Nano-based antimicrobial technology can be integrated into personal equipment for the greater safety of healthcare workers and people. Various nanomaterials such as quantum dots can be used as biosensors to diagnose COVID-19. Nanotechnology offers benefits from the use of nanosystems, such as liposomes, polymeric and lipid nanoparticles, metallic nanoparticles, and micelles, for drug encapsulation, and facilitates the improvement of pharmacological drug properties. Antiviral functions for nanoparticles can target the binding, entry, replication, and budding of COVID-19. The toxicity-related inorganic nanoparticles are one of the limiting factors of its use that should be further investigated and modified. In this review, we are going to discuss nanomedicine options for COVID-19 management, similar applications for related viral diseases, and their gap of knowledge.

Citing Articles

Emerging Applications of Nanotechnology in Healthcare and Medicine.

Malik S, Muhammad K, Waheed Y Molecules. 2023; 28(18).

PMID: 37764400 PMC: 10536529. DOI: 10.3390/molecules28186624.


Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.

Rahman A, Roy K, Deb G, Ha T, Rahman S, Aktar M Int J Mol Sci. 2023; 24(17).

PMID: 37685938 PMC: 10488153. DOI: 10.3390/ijms241713130.


Lyophilization Based Isolation of Exosomes.

Qazi R, Sajid Z, Zhao C, Hussain I, Iftikhar F, Jameel M Int J Mol Sci. 2023; 24(13).

PMID: 37445655 PMC: 10341925. DOI: 10.3390/ijms241310477.


An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.

Tajnur R, Rezwan R, Aziz A, Islam M Health Sci Rep. 2023; 6(7):e1377.

PMID: 37404449 PMC: 10315735. DOI: 10.1002/hsr2.1377.


Superior possibilities and upcoming horizons for nanoscience in COVID-19: noteworthy approach for effective diagnostics and management of SARS-CoV-2 outbreak.

Bhattacharjee B, Ikbal A, Farooqui A, Sahu R, Ruhi S, Syed A Chem Zvesti. 2023; :1-24.

PMID: 37362791 PMC: 10072050. DOI: 10.1007/s11696-023-02795-3.


References
1.
Donaldson K, Murphy F, Duffin R, Poland C . Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol. 2010; 7:5. PMC: 2857820. DOI: 10.1186/1743-8977-7-5. View

2.
Block P, Hoffman M, Raabe I, Dowd J, Rahal C, Kashyap R . Social network-based distancing strategies to flatten the COVID-19 curve in a post-lockdown world. Nat Hum Behav. 2020; 4(6):588-596. DOI: 10.1038/s41562-020-0898-6. View

3.
Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

4.
Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A . Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015; 495(1):439-446. DOI: 10.1016/j.ijpharm.2015.09.014. View

5.
Paul A, Shi Y, Acharya D, Douglas J, Cooley A, Anderson J . Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J Gen Virol. 2014; 95(Pt 8):1712-1722. PMC: 4103068. DOI: 10.1099/vir.0.066084-0. View